Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretins secreted in response to oral glucose ingestion by intestinal L and K cells, respectively. The molecular mechanisms responsible for intestinal cell glucose sensing are unknown but could be related to those described for ␤-cells, brain and hepatoportal sensors. We determined the role of GLUT2, GLP-1 or GIP receptors in glucose-induced incretins secretion, in the corresponding knockout mice. GLP-1 secretion was reduced in all mutant mice, while GIP secretion did not require GLUT2. Intestinal GLP-1 content was reduced only in GIP and GLUT2 receptors knockout mice suggesting that this impairment could contribute to the phenotype. Intestinal GIP content was similar in all mice studied. Furthermore, the impaired incretins secretion was associated with a reduced glucose-stimulated insulin secretion and an impaired glucose tolerance in all mice. In conclusion, both incretins secretion depends on mechanisms involving their own receptors and GLP-1 further requires GLUT2.
Introduction
Glucagon-like peptide-1 (GLP-1) and the glucose dependent insulinotropic polypeptide (GIP) are strong activators of glucose-induced insulin secretion (Holst and Gromada, 2004; Drucker, 1998) . A major characteristic of both incretin secretion and action is a strict glucose-dependency, which confers a therapeutic advantage for incretin-based approaches for the treatment of type 2 diabetes (Zander et al., 2002) . Whereas considerable evidence supports a direct pancreatic effect of these peptides for the control of glucose-induced insulin secretion, recent data support a role for extrapancreatic GLP-1 actions, including activation of the portal glucose sensor in the control of glucose * Corresponding authors at: I 2 MR, IFR31, CHU Rangueil, BP 84225, 31432
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homeostasis (Balkan et al., 1999; Knauf et al., 2005; Preitner et al., 2004) . Activation of the portal glucose sensor depends on the absorption of glucose from the gut, triggering of glucose sensitive cells located in the enteric/hepatoportal area. Hepatoportal glucose administration engages the central (CNS) and autonomic nervous systems (ANS) and subsequent transmission of the glucose signal, leading to improved glucose clearance and enhanced ␤-cell function (Adachi et al., 1984; Burcelin et al., 2000a; Stumpel et al., 1998; Stumpel and Jungermann, 1997) . The CNS connected to the intestine and the endocrine pancreas via the vagus nerve controls the secretion of these hormones (Rocca and Brubaker, 1999) . Hence, both the direct and indirect GLP-1-dependent routes for the control of insulin secretion could contribute to the benefical incretin effect in type 2 diabetes.
Surprisingly little is known about the molecular mechanisms of glucose-induced incretin secretion. Studies using GLUTag cells, a model of enteroendocrine L-cells showed that metabolizable carbohydrates (glucose/fructose) stimulate GLP-1 secretion by the mean of the closing of K-ATP sensitive channels (Gribble et al., 2003) . This mechanism seems to be similar to the one described for the insulin secreting ␤-cell. Furthermore, an important regulator of both ␤-cells and L intestinal cells is the ANS (Hansen et al., 2004; Rocca and Brubaker, 1999) . We have previously shown that the glucose transporter GLUT2 and the GLP-1 receptor are key mechanisms required for glucosedependent insulin secretion (Guillam et al., 1997; Thorens and Waeber, 1993) and for function of the hepatoportal vein glucose sensor (Burcelin et al., 2000b) . To examine the importance of these same molecular mechanisms for the control of more proximal steps in the regulation of glucose-induced-incretin secretion, we characterized incretin secretion in GLUT2 and incretin receptors knockout mice.
Methods

Mice models and surgical procedures
GLUT2 deficient mice were from our colony as previously described (Guillam et al., 1997) . Briefly, GLUT2 null mice die between 2 and 3 weeks of age (Guillam et al., 1997) . Transgenic reexpression of GLUT1 or GLUT2 specifically in pancreatic ␤ cells under the control of the rat insulin promoter (RIP) allows the mice to survive, breed, and normally secrete insulin in response to hyperglycemia. These mice were in a mixed background of C57BL/6 and SV129 and were studied at the age of 12-16 weeks (ripglut1; glut2). The GLP-1 receptor knock out mice (GLP-1R−/−) were in a mixed C57BL/6 and SV129 background and have been extensively characterized (Scrocchi et al., 1996) . The GIP receptor knockout mice (GIPR −/−) were in a mixed C57BL/6 and SV129 background and have been extensively characterized (Preitner et al., 2004) .
Under anesthesia (ketamine/xylazine i.p., 100 and 10 mg/kg, respectively) a catheter was indwelled into the stomach as previously described (Knauf et al., 2005) . Briefly, after hair shaving a 4 mm laparotomy was performed on the left side of the mouse at the level of the stomach. The stomach was gently extracted and a needle hole was performed on the proximal part of the stomach to introduce 5 mm of one extremity a teflon catheter. It was secured into the stomach by the use of surgical glue (Histoacryl, 3 M Health Care, MN). The other extremity of the catheter was tunneled under the skin and exteriorized at the back of the neck. After surgery the mice were housed individually and were allowed to recover from surgery for 1 week. Only the mice that fully recovered their body weight were studied further. All animal experimental procedures were approved by the Rangueil Hospital Committee of the Rangueil Hospital, Toulouse, France.
Glucose tolerance test (gtt)
The mice were fasted overnight. 3 g/kg of glucose or water (∼100 l) were injected over 30 s into the stomach catheter. For hormonal determinations, portal blood was collected after 15 min (considered as the time point giving the highest value of the time course (Herrmann et al., 1995) ) onto a mixture of 1 g/ml of aprotinin and 0.1 mM EDTA. The portal blood was sampled as previously described (Cani et al., 2006) ; 250 l of blood can be easily sampled using this technique. Plasma was aliquoted and kept at −70 • C until assayed for insulin, GLP-1, and GIP concentrations. On different sets of mice systemic blood glucose concentrations were determined before and at 0, 15, 30, 60, and 90 min after glucose or water injection using a glucose meter (Roche Diagnostic, Meylan, France).
Hormonal determinations
Plasma insulin (ELISA kit, Mercodia, Upssala, Sweden) concentrations were determined (RIA kit, Linco Research, St. Charles, USA). Intra and inter assay coefficient of variations were for both below 5% and 15%, respectively. GIP and GLP-1 concentrations in plasma were measured after extraction of plasma with 70% ethanol (v/v, final concentration). For the GIP radioimmunoassay (Krarup et al., 1983) we used the C-terminally directed antiserum R 65, which crossreacts fully with human GIP but not with the so-called GIP 8000, whose chemical nature and relationship to GIP secretion is uncertain. Human GIP and 125-I human GIP (70 MBq/nmol) were used for standards and tracer. The plasma concentrations of GLP-1 were measured (Orskov et al., 1994) against standards of synthetic GLP-1 7-36amide using antiserum code no. 89390, which is specific for the amidated C-terminus of GLP-1 and therefore does not react with GLP-1-containing peptides from the pancreas. The results of the assay accurately reflect the rate of secretion of GLP-1 because the assay measures the sum of intact GLP-1 and the primary metabolite, GLP-1 9-36amide, into which GLP-1 is rapidly converted (Deacon et al., 1996) . For both assays, sensitivity was below 1 pmol/l, intra assay coefficient of variation below 6% at 20 pmol/l, and recovery of standard, added to plasma before extraction, about 100% when corrected for losses inherent in the plasma extraction procedure. Plasma GLP-1 and GIP concentrations were determined as previously described (Hansen et al., 2004) . Intestinal content of incretins was determined by radioimmunoassay after extraction of intestinal biopsies (duodenum for GIP assay and ileon and colon for GLP-1 assay) by the method for small samples as described (Holst and Bersani, 1991) .
Statistical analysis
Results are presented as mean ± S.E. Significant differences were analyzed by using Student's t-test for unpaired bilaterally distributed values of equal variance, by using GraphPad Prism version 4.00 for windows (GraphPad Software, San Diego, CA, USA; www.graphpad.com). Values were considered different when P < 0.05. 
Results
Portal incretin concentration during intragastric glucose tolerance test
Fifteen minutes after the glucose challenge the portal vein concentration of GLP-1 increases more than 10 times in wild type mice (Fig. 1A) . This increase was reduced by 80% in GLP-1 receptor and 55% in GLUT2 and GIP receptor knockout mice. No difference in plasma GLP-1 levels was observed in the basal fasted state.
The glucose challenge also induced a ten-fold increase in hepatoportal GIP concentration in wild type mice. This increase was also reduced by 40% in GLP-1 and GIP receptor knockout mice (Fig. 1B) . Conversely to GLP-1, glucose-induced GIP secretion was normal in GLUT2 knockout mice suggesting that the secretion of the hormone was regulated differently compared to GLP-1 but independent of a GLUT2-sensitive mechanism as described for most other glucose sensors (Burcelin et al., 2000b; Guillam et al., 1997; Leloup et al., 1998; Marty et al., 2005) . Mutant mice showed glucose intolerance, as previously described (Preitner et al., 2004) , (Fig. 2A ) which was associated with a reduced portal vein concentration of insulin (Fig. 2B) .
Incretins intestinal content
The impaired incretin secretion of the mutant mice could be related to a reduced intestinal content of GLP-1 or GIP. Hence, we quantified the GLP-1 and GIP intestinal content in control and mutant mice. Intestinal GLP-1 content was reduced by 50% in GLUT2 and GIP receptor mutant mice, suggesting that the GIP and GLUT2 receptors generate signals required for optimal synthesis of intestinal GLP-1 (Fig. 3A) . Conversely, no differences were detected for GIP content (Fig. 3B) . These data could suggest that the reduced secretion of GIP in incretin receptor mutant mice is likely related to the incretin dependency of the secretory system rather than to a reduced intestinal content of the hormone. 
Discussion
The present data show that the incretin receptors are both required for the regulation of oral glucose-induced GLP-1 and GIP secretions and that GLUT2 is also required for GLP-1 secretion. As opposed to GIP, GLP-1 synthesis requires GIP and GLUT2 receptors.
Therapeutic strategies enhancing glucose-stimulated incretin secretion might be useful for the treatment of diabetes as these hormones are released at the vicinity of their most proximal physiological target, the enteric glucose sensor. Type 2 diabetes is characterized by a lower plasma GLP-1 release after a glucose load, one strategy could consist in stimulating endogenous incretin secretion (Vilsboll et al., 2003) . Recently, we have shown that a 4-week treatment with dietary fibres attenuated the development of high-fat diet-induced diabetes (Cani et al., 2006) by a mechanism requiring the GLP-1 receptor. We conclude that GLP-1 secretion into the portal vein area was important to mediate the hormonal effect. The systemic injection of GLP-1 as a therapeutic strategy does not increase portal GLP-1 concentration and cannot activate the hepatoportal glucose sensors (Burcelin et al., 2001 ). Conversely, DPPIV-inhibitors can increase the GLP-1 portal concentration, activate the GLP-1 receptor and consequently engage the hepatoportal system.
We show that, in absence of at least one of the incretin receptors, secretion of both incretins is impaired in response to an oral glucose challenge. This data suggests the existence of an autoregulatory loop enhancing the secretion of the incretin themselves (Fig. 4) . We further demonstrate that impaired GLP-1 secretion in GLP-1 receptor knockout mice was not related to reduced-intestinal hormone content. These findings indicate that the GLP-1 receptor is required for normal glucose-dependent control of GLP-1 secretion. It has been shown that GLP-1 secretion is dependent on the integrity of the enteric parasympathetic branch of the autonomous nervous system and inhibited by the sympathetic nervous system (Hansen et al., 2004 ). In our model, glucose increases portal GLP-1 concentrations by 10 times in wild type mice. This increase was reduced by 80% in GLP-1 and 55% in GLUT2 and GIP receptors knockout, suggesting that GLP-1, GIP and GLUT2 receptors are required for the secretion of incretins by the mean of a nervous signaling pathway and the ANS. Reinforcing this hypothesis is the fact that vagotomy prevents GLP-1 secretion (Rocca and Brubaker, 1999) . Our data also implicates a role for the glucose transporter GLUT2 in the control of GLP-1 secretion. GLUT-2 is expressed in the CNS (Leloup et al., 1994) and required for ANS-mediated hepatoportal glucose sensing (Burcelin et al., 2000b) . However, glucose enters the epithelial cell through the sodium-glucose cotransporter SGLT-1 (Turk et al., 1991) and is released into the mesenteric blood through GLUT2. We could suggest that the GLUT2-dependent enteric glucose absorption is not a major regulatory mechanism for enteric glucose sensing. A complementary set of evidence has also suggested that carbohydrate receptors exist in the lumen of the intestine (Dyer et al., 2003a (Dyer et al., ,b, 2005 . Interestingly, the intestinal GLP-1 content was reduced in GLUT2 and GIP receptor KO but not in GLP-1 receptor KO mice. This shows the importance of these molecular mechanisms for the regulation of GLP-1 synthesis which could contribute in part to the impaired secretion of the hormone. Conversely, GIP secretion in response to glucose did not require GLUT2 but did involve both incretin receptors. These impairments were not simply attributable to reduced intestinal stores of GIP since intestinal GIP content was normal in mutant mice. Other authors have previously shown that GLP-1 receptors knock out mice exhibited an exacerbate GIP secretion in response to an oral glucose load (Pederson et al., 1998) . The involvement of the ANS in the regulation of GIP secretion has not been demonstrated, suggesting a direct effect of glucose on K cells. The majority of K cells are located in the duodenum where glucose is absorbed and could be in direct contact with glucose for the stimulation of GIP release. Again, this mechanism does not involve GLUT2 as this transporter is not an obligatory mechanism for transepithelial glucose transport and GIP secretion was normal in GLUT2 mutant mice (Stumpel and Jungermann, 1997) . The regulatory roles of GIP and GLP-1 receptors on GIP secretion cannot be fully explained by our present data but suggest that one or more cell types, required for transduction of an enteral glucose signal, are defective in incretin receptor knock out mice. The decrease in GLP-1 content of GLUT2 and GIP receptor knock out mice could also be attributed to modification in L-cell number, structure and/or differentiation. Reinforcing this hypothesis, we have recently demonstrated that the increase in colonic GLP-1 content was associated to a higher L-cells differentiation and total cell number (Cani et al., 2007) . Diabetes is characterized by a state of glucose unresponsiveness. Therefore, another possible explanation, responsible for the altered GLP-1 secretion in response to oral glucose load in the knock out mice, would be the impairment of the enteric glucose sensing system in the GLUT2 and GLP-1 receptor knock out mice.
In conclusion, our study provides new insights into the molecular mechanisms controlling glucose-dependent incretin secretion. Our data illustrates a previously unappreciated essential role for GLP-1 and GIP receptors in the control of incretin secretion while GLUT2 is only required for the secretion of GLP-1. Strategies which aim to enhance intestinal glucose sensing might help to stimulate the physiological release of incretin hormones, thereby providing a valuable adjunctive approach for the treatment of type 2 diabetes.
